Dr. Amal S. Aly is an accomplished physician-scientist and double board-certified in Clinical cytogenetics and Molecular Genetics with a distinguished career spanning clinical medicine, academic research, and diagnostic laboratory leadership. She holds an M.D. from Al Azhar Medical School in Cairo, Egypt, where she also completed her residency in Obstetrics and Gynecology and served as a faculty member. Driven by a passion for biomedical research, she secured a competitive government grant to pursue her doctoral studies in the United States.
Her early research endeavors in the U.S. included work on pre-eclampsia at Temple University and the University of Pennsylvania, where she collaborated with Dr. Samuel Parry. This research, focused on placental biology and trophoblast function, led to a peer-reviewed publication in the American Journal of Obstetrics and Gynecology.
Determined to deepen her scientific expertise, Dr. Aly pursued a PhD. in Molecular Biosciences at the University of Medicine and Dentistry of New Jersey. Her work, which revealed significant insights into cancer cell resistance mechanisms and therapeutic vulnerabilities, was supported by a competitive pre-doctoral fellowship from the U.S. Department of Defense Breast Cancer Research Program. Her findings were published in Nature Structural & Molecular Biology and Journal of Molecular Cell Biology and earned her multiple awards from the New Jersey Commission on Cancer Research and other institutions.
Transitioning into applied clinical diagnostics, Dr. Aly took on leadership roles at prestigious laboratories in USA. At Coriell Institute for Medical Research, she served as Cytogenomics Manager, overseeing cytogenetic analyses, managing services for external researchers, and reporting on array CGH, methylation, microsatellite instability, and sequencing data using platforms such as Affymetrix SNP 6.0 and Ion Torrent. During that time Dr. Aly undertook her Clinical Genetics fellowship at NJ Medical School then she sat for the board contribution by ABMGG.
She then served as Cytogenetic Director at Quest Diagnostics, with responsibilities including case review and sign-out for karyotyping and FISH, clinician interaction, and laboratory oversight. She was the Cytogenetic Director and Co-director of the Molecular Lab at siParadigm Clinical Diagnostics from 2018-2021, where she focuses on oncology and hematologic malignancies. She leads operations for cytogenetic and NGS testing (e.g., MDS, CLL, MPN, hereditary cancer panels), ensures regulatory compliance (CLIA, CAP, NY/NJ state), and oversees QA/QC programs. Between 2018 to 2024, Dr. Aly was appointed as the Molecular Medical Director and Cytogenetics Director for PsiGenex and PathGroup.
Currently, Dr. Aly is the head of Diagnostic Genomics Division (DGD) and Acting Vice-Chair Clinical Services for DLMP.
Dr. Aly’s unique combination of clinical, academic, and operational experience equips her to contribute meaningfully to complex, multidisciplinary environments. Her journey from a clinical physician in Egypt to a respected researcher and diagnostic lab director in the U.S. reflects both resilience and a commitment to advancing patient care.
